You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
輔助生殖、三胎、教育股集體走強,北京16項輔助生殖技術項目納入醫保報銷
格隆匯2月21日丨受“北京16項輔助生殖技術項目納入醫保報銷,輔助生殖進入醫保迎來破局”消息刺激,港A兩地輔助生殖、三胎和教育股今日盤中集體上漲。A股康芝藥業、悦心健康、漢商集團、澳洋健康、傳智教育、凱文教育等午後漲停,港股錦欣生殖和貝康醫療盤中均大漲超10%。北京商報稱,近日,北京市醫保局會同市衞生健康委等部門印發《關於規範調整部分醫療服務價格項目的通知》,對63項醫療服務價格項目進行規範調整,同時,市醫保局、市人力社保局同步配套了醫保及工傷報銷政策。其中,為實施積極生育支持措施,通過組織專家論證,在費用可控、確保醫保基金可承受的基礎上,將門診治療中常見的宮腔內人工授精術、胚胎移植術、精子優選處理等16項涉及人羣廣、診療必需、技術成熟、安全可靠的輔助生殖技術項目納入醫保甲類報銷範圍。新政策將於3月26日落地。有分析人士指出,通知的印發意味着監管重拳方案落地,在政策層面上重視輔助生殖行業;參考日韓歐美,此舉有望帶動輔助生殖行業滲透率大大提升,提高行業規模。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account